Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 8/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | DCPS | Q96C86 | 3/20 | 0.36 |
| ▸ | DHFR | P00374 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CYBB | P04839 | 1/20 | 0.35 |
| ▸ | NOX5 | Q96PH1 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | FLT1 | P17948 | 1/20 | 0.35 |
| ▸ | MIF | P14174 | 1/20 | 0.35 |
| ▸ | IKBKB | O14920 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16011941 | 0.81 | ALDH1A1 (0.53) | TSHRDCPSDHFRKDM4EALDH1A1 | |
| SCHEMBL1192087 | 0.81 | EGFR (0.45) | NCF1TSHRKDM1AEGFRJAK2 | |
| SCHEMBL27248729 | 0.74 | TLR8 (0.40) | TSHRDCPSDHFRKDM4EALDH1A1 | |
| SCHEMBL27248810 | 0.73 | NCF1 (0.44) | NCF1TSHRKDM1ADCPSDHFR | |
| SCHEMBL1154579 | 0.73 | DCPS (0.68) | NCF1DCPSDHFR | |
| SCHEMBL3402989 | 0.72 | DCPS (0.50) | NCF1DCPSDHFR | |
| SCHEMBL29041258 | 0.72 | NCF1 (0.52) | NCF1TSHRDCPSDHFRCYBB | |
| SCHEMBL27248935 | 0.71 | KCNH2 (0.38) | DCPSKDM4EALDH1A1HPGDMAPT | |
| SCHEMBL3686238 | 0.70 | NCF1 (0.49) | NCF1TSHRKDM1AEGFRKDM4E | |
| SCHEMBL1192699 | 0.69 | KDM1A (0.45) | NCF1TSHRKDM1AEGFRHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360085-A1 | Glucose Uptake Inhibitors | KADMON CORPORATION, LLC (US) | 2024-10-31 | — | — | US | disclosed |
| US-12030857-B2 | Glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030857-B2 | Glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030857-B2 | Glucose uptake inhibitors | KADMON CORPORATION, LLC (US) | 2024-07-09 | — | — | US | disclosed |
| US-20220363648-A1 | Glucose Uptake Inhibitors | KADMON CORPORATION, LLC | 2022-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030857-B2 | Glucose uptake inhibitors | SLC2A1, SLC2A4, SLC2A2 | NCF1 1313/4885TSHR 3168/4885KDM1A 2270/4885 |
| US-20220363648-A1 | Glucose Uptake Inhibitors | SLC2A1, SLC2A4, SLC2A2 | NCF1 1313/4885TSHR 3168/4885KDM1A 2270/4885 |
| US-20240360085-A1 | Glucose Uptake Inhibitors | SLC2A3, SLC2A1, SLC2A4 | NCF1 1399/4885TSHR 2854/4885KDM1A 1991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.